Claudia Mera1, Iván Godoy1, Renato Ramírez1, Jackeline Moya1, María Paz Ocaranza2, Jorge E Jalil3. 1. Pontificia Universidad Católica de Chile, School of Medicine, Division of Cardiovascular Diseases, Laboratory of Molecular Cardiology, Santiago, Chile. 2. Advanced Center for Chronic Diseases (ACCDiS), Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, ChileDivision of Cardiovascular Diseases, School of Medicine, Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. 3. Pontificia Universidad Católica de Chile, School of Medicine, Division of Cardiovascular Diseases, Marcoleta 367 Piso 8, Santiago, Chile jjalil@med.puc.cl.
Abstract
OBJECTIVE: The objective of this study was to determine the molecular mechanisms by which cardiac Rho-associated coiled-coil containing protein kinase (ROCK) activation after myocardial infarction (MI) does intervene in cardiac systolic function decline and remodeling. METHODS: Simultaneous measurement of different cardiac ROCK target proteins levels, in vivo left ventricular (LV) systolic function, myocardial fibrosis and hypertrophy in rats with MI under ROCK inhibition with fasudil. RESULTS: Seven days after MI, the ventricular mass increased significantly by 5.6% in the MI group and was reduced with fasudil. LV systolic dysfunction improved significantly with fasudil whereas cardiac ROCK activation was reduced to sham levels. The ROCK inhibitor also reduced increased cardiac levels of both ROCK1 and ROCK2 isoforms, cardiomyocyte ROCK2 fluorescence levels and β-myosin heavy chain (MHC) levels in addition to myocardial collagen volume fraction decline. Compared with sham rats, troponin phosphorylation levels after MI were similar and ROCK inhibition reduced them. MI significantly increased phosphorylation levels of extracellular-signal-regulated kinase (ERK) 42 and ERK 44 by twofold and 63%, respectively, whereas in the fasudil-treated MI group these levels were similar to those in the sham group. MI significantly increased phosphorylated levels of the transcription factor GATA-4 and the ROCK inhibitor normalized them. CONCLUSIONS: LV systolic dysfunction after MI was strongly associated with cardiac ROCK activation and subsequent phosphorylation of ROCK target proteins that promote ventricular remodeling such as β-MHC and the ERK/GATA-4 pathway. ROCK inhibition with fasudil significantly improved systolic function, diminished myocardial fibrosis and normalized β-MHC and ERK/GATA-4 phosphorylation levels.
OBJECTIVE: The objective of this study was to determine the molecular mechanisms by which cardiac Rho-associated coiled-coil containing protein kinase (ROCK) activation after myocardial infarction (MI) does intervene in cardiac systolic function decline and remodeling. METHODS: Simultaneous measurement of different cardiac ROCK target proteins levels, in vivo left ventricular (LV) systolic function, myocardial fibrosis and hypertrophy in rats with MI under ROCK inhibition with fasudil. RESULTS: Seven days after MI, the ventricular mass increased significantly by 5.6% in the MI group and was reduced with fasudil. LV systolic dysfunction improved significantly with fasudil whereas cardiac ROCK activation was reduced to sham levels. The ROCK inhibitor also reduced increased cardiac levels of both ROCK1 and ROCK2 isoforms, cardiomyocyte ROCK2 fluorescence levels and β-myosin heavy chain (MHC) levels in addition to myocardial collagen volume fraction decline. Compared with sham rats, troponin phosphorylation levels after MI were similar and ROCK inhibition reduced them. MI significantly increased phosphorylation levels of extracellular-signal-regulated kinase (ERK) 42 and ERK 44 by twofold and 63%, respectively, whereas in the fasudil-treated MI group these levels were similar to those in the sham group. MI significantly increased phosphorylated levels of the transcription factor GATA-4 and the ROCK inhibitor normalized them. CONCLUSIONS:LV systolic dysfunction after MI was strongly associated with cardiac ROCK activation and subsequent phosphorylation of ROCK target proteins that promote ventricular remodeling such as β-MHC and the ERK/GATA-4 pathway. ROCK inhibition with fasudil significantly improved systolic function, diminished myocardial fibrosis and normalized β-MHC and ERK/GATA-4 phosphorylation levels.
Authors: Juozas A Zavadzkas; Rupak Mukherjee; William T Rivers; Risha K Patel; Evan C Meyer; Laurel E Black; Richard A McKinney; J Marshall Oelsen; Robert E Stroud; Francis G Spinale Journal: Am J Physiol Heart Circ Physiol Date: 2011-06-10 Impact factor: 4.733
Authors: Javier E López; Bat-Erdene Myagmar; Philip M Swigart; Megan D Montgomery; Stephen Haynam; Marty Bigos; Manoj C Rodrigo; Paul C Simpson Journal: Circ Res Date: 2011-07-21 Impact factor: 17.367
Authors: G de Simone; R B Devereux; A Ganau; R T Hahn; P S Saba; G F Mureddu; M J Roman; B V Howard Journal: Am J Cardiol Date: 1996-10-01 Impact factor: 2.778
Authors: Alexander Khromov; Nandini Choudhury; Andra S Stevenson; Avril V Somlyo; Masumi Eto Journal: J Biol Chem Date: 2009-06-15 Impact factor: 5.157
Authors: Maria Paz Ocaranza; Jorge E Jalil; Rodrigo Altamirano; Ana de León; Jackeline Moya; Alejandra Lonis; Luigi Gabrielli; Paul Mac Nab; Samuel Córdova; Alejandro Paredes; Ismael Vergara; Alex Bittner; Karime Sabat; Karla Pastorini Journal: Front Pharmacol Date: 2021-04-23 Impact factor: 5.810
Authors: Olivia J Robertson-Gray; Sarah K Walsh; Erik Ryberg; Ann-Cathrine Jönsson-Rylander; Christopher Lipina; Cherry L Wainwright Journal: Pharmacol Res Perspect Date: 2019-05-24
Authors: Maria Paz Ocaranza; Jackeline Moya; Jorge E Jalil; Sergio Lavandero; Alexis M Kalergis; Cristián Molina; Luigi Gabrielli; Iván Godoy; Samuel Córdova; Pablo Castro; Paul Mac Nab; Victor Rossel; Lorena García; Javier González; Cristián Mancilla; Camila Fierro; Luis Farías Journal: J Cell Mol Med Date: 2019-11-28 Impact factor: 5.310
Authors: Christina Nalkurthi; Wayne A Schroder; Michelle Melino; Katharine M Irvine; Melanie Nyuydzefe; Wei Chen; Jing Liu; Michele W L Teng; Geoffrey R Hill; Patrick Bertolino; Bruce R Blazar; Gregory C Miller; Andrew D Clouston; Alexandra Zanin-Zhorov; Kelli P A MacDonald Journal: JHEP Rep Date: 2021-10-06
Authors: Shunsuke Miyahara; Alexander Jenke; Mariam Yazdanyar; Julia Kistner; Moritz Benjamin Immohr; Yukiharu Sugimura; Hug Aubin; Hiroyuki Kamiya; Yutaka Okita; Artur Lichtenberg; Payam Akhyari Journal: Asian Cardiovasc Thorac Ann Date: 2022-07-15
Authors: Tadeu L Montagnoli; Jaqueline S da Silva; Susumu Z Sudo; Aimeé D Santos; Gabriel F Gomide; Mauro P L de Sá; Gisele Zapata-Sudo Journal: Cells Date: 2021-06-30 Impact factor: 7.666